Tissue360 Newsletter
Archive/Subscribe | TAPPI.org | Advertise | TAPPI Press Catalog January 2022

Essity Signs Euro 300 million Loan Agreement at Favorable Terms With EIB

Print Print this Article | Send to Colleague

The EUR 300m will support Essity’s product innovation and sustainability investments across all business areas and product segments until 2024. The loan has a tenor of 7 years.

“We are pleased with the support from EIB for our comprehensive innovation process. Essity’s focus is to increase wellbeing for people everywhere as we continue our journey to reach net-zero greenhouse gas emissions by 2050,” says Magnus Groth, president & CEO of Essity.

At the Capital Markets Day in November 2021, Essity presented its roadmap to Net Zero where breakthrough technologies and innovation play a key role. Essity has set a target that more than 50 percent of the innovations shall yield social and/or environmental improvements.

Essity is a leading global hygiene and health company. We are dedicated to improving well-being through our products and services. Sales are conducted in approximately 150 countries under the leading global brands TENA and Tork, and other strong brands, such as JOBST, Leukoplast, Libero, Libresse, Lotus, Nosotras, Saba, Tempo, Vinda and Zewa. Essity has about 46,000 employees. Net sales in 2020 amounted to approximately SEK 122bn (EUR 11.6bn). The company’s headquarters is located in Stockholm, Sweden, and Essity is listed on Nasdaq Stockholm. Essity breaks barriers to well-being and contributes to a healthy, sustainable and circular society.



Back to Tissue360 Newsletter

American Roller and Plasma Coatings
Köerber Tissue